Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-096 Phase 1 Safety and PK in Healthy Volunteers
NCT05915247Phase 1Completed
- Sponsor
- Herantis Pharma
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HER-096 in Parkinson's disease (PD) (3 arms), sponsored by Herantis Pharma. Primary endpoints: Adverse Events (AEs) at 8 days, Physical examination findings at 8 days and 4 more. Started Mar 2023; status: completed.
02
Drugs
HER-096
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05915247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05915247.